Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on first-line immunomodulatory treatment with fingolimod vs. platform injectables

被引：0
|
作者：
von Wyl, V. [1 ]
Benkert, P. [2 ]
Lorscheider, J. [3 ,4 ]
Hanni, P. [5 ]
Lienert, C. [6 ]
Decard, B. [3 ,4 ]
Kuhle, J. [3 ,4 ]
Derfuss, T. [3 ,4 ]
Kappos, L. [3 ,4 ]
Yaldizli, O. [3 ,4 ]
机构：
[1] Univ Zurich, Dept Epidemiol Biostat & Prevent, Zurich, Switzerland
[2] Univ Hosp Basel, Dept Clin Res, Clin Trial Unit, Basel, Switzerland
[3] Univ Hosp Basel, Dept Med, Neurol Clin & Policlin, Basel, Switzerland
[4] Univ Basel, Basel, Switzerland
[5] Swiss Assoc Joint Tasks Hlth Insurers, Solothurn, Switzerland
[6] Rheinburg Clin, Dept Neurol, Walzenhausen, Switzerland
来源：
MULTIPLE SCLEROSIS JOURNAL | 2019年 / 25卷
基金：
新加坡国家研究基金会;
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
P751
引用
收藏
页码：381 / 382
页数：2
相关论文
共 50 条
  • [1] Progression independent of relapse activity (PIRA) in relapsing-remitting multiple sclerosis patients on injectable vs oral first line Disease Modifying Therapies: an Italian MS registry study
    Zanghi, A.
    Avolio, C.
    Amato, M. P.
    Filippi, M.
    Trojano, M.
    D'Amico, E.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 976 - 977
  • [2] Progression independent of relapse activity (PIRA) is associated with accelerated retinal atrophy in patients with relapsing remitting multiple sclerosis
    Strauss, Eva-Maria
    Aly, Lilian
    Berthele, Achim
    Lambrecht, Sebastian
    Hemmer, Bernhard
    Knier, Benjamin
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 1075 - 1076
  • [3] Utility of Progression Independent of Relapse Activity as a Trial Outcome in Relapsing-Remitting Multiple Sclerosis
    Strijbis, Eva M. M.
    Mostert, Jop
    Comtois, Jacynthe
    Salter, Amber
    Repovic, Pavle
    Bowen, James D.
    Uitdehaag, Bernard M. J.
    Cutter, Gary R.
    Koch, Marcus W.
    NEUROLOGY, 2025, 104 (02)
  • [4] Can a physician predict the clinical response to first-line immunomodulatory treatment in relapsing-remitting multiple sclerosis?
    Mezei, Zsolt
    Bereczki, Daniel
    Racz, Lilla
    Csiba, Laszlo
    Csepany, Tuende
    NEUROPSYCHIATRIC DISEASE AND TREATMENT, 2012, 8 : 465 - 473
  • [5] Cost analysis of glatiramer acetate vs. fingolimod for the treatment of patients with relapsing-remitting multiple sclerosis in Spain
    Sanchez-de la Rosa R.
    Sabater E.
    Casado M.A.
    Health Economics Review, 3 (1) : 1 - 5
  • [6] Course of therapy in patients with active relapsing-remitting multiple sclerosis despite first-line treatment
    Bartosik-Psujek, Halina
    Adamczyk-Sowa, Monika
    Kulakowska, Alina
    Glazewska, Joanna
    Smaga, Anna
    Brola, Waldemar
    POSTEPY PSYCHIATRII I NEUROLOGII, 2023, 32 (02): : 59 - 67
  • [7] Progression independent of relapse activity is associated with increased brain atrophy rates in patients with relapsing-remitting multiple sclerosis
    Cagol, A.
    Schaedelin, S.
    Barakovic, M.
    Benkert, P.
    Todea, R. -A.
    Rahmanzadeh, R.
    Galbusera, R.
    Lu, P. -J.
    Weigel, M.
    Melie-Garcia, L.
    Ruberte, E.
    Radue, E. -W.
    Yaldizli, O.
    Oechtering, J.
    Sinnecker, T.
    Lorscheider, J.
    Mueller, S.
    Achtnichts, L.
    Vehoff, J.
    Disanto, G.
    Findling, O.
    Chan, A.
    Salmen, A.
    Pot, C.
    Bridel, C.
    Zecca, C.
    Derfuss, T.
    Lieb, J. M.
    Remonda, L.
    Wagner, F.
    Vargas, M.
    Du Pasquier, R.
    Lalive, P.
    Pravata, E.
    Weber, J.
    Gobbi, C.
    Leppert, D.
    Kappos, L.
    Kuhle, J.
    Granziera, C.
    MULTIPLE SCLEROSIS JOURNAL, 2021, 27 (2_SUPPL) : 98 - 99
  • [8] Natalizumab versus fingolimod in patients with relapsing-remitting multiple sclerosis non-responding to first-line injectable therapies
    Baroncini, Damiano
    Ghezzi, Angelo
    Annovazzi, Pietro O.
    Colombo, Bruno
    Martinelli, Vittorio
    Minonzio, Giorgio
    Moiola, Lucia
    Rodegher, Mariaemma
    Zaffaroni, Mauro
    Comi, Giancarlo
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 (10) : 1315 - 1326
  • [9] Cost minimisation analysis of fingolimod vs natalizumab as a second line of treatment for relapsing-remitting multiple sclerosis
    Crespo, C.
    Izquierdo, G.
    Garcia-Ruiz, A.
    Granell, M.
    Brosa, M.
    NEUROLOGIA, 2014, 29 (04): : 210 - 217
  • [10] Impact of continuous fingolimod therapy and switching to fingolimod on relapse severity in patients with relapsing-remitting multiple sclerosis
    Haas, J.
    Vollmer, T.
    Jeffery, D.
    Meier, D. Piani
    Stadler, B.
    Ritter, S.
    Cohen, J.
    Hartung, H. P.
    MULTIPLE SCLEROSIS JOURNAL, 2016, 22 : 636 - 636
12345